Cosmo Pharmaceuticals announces denial of Methylene Blue MMX appeal and beginning of activity to start second phase III trial
Cosmo Pharmaceuticals N.V. today provided a regulatory update for Methylene Blue MMX, an investigational new drug product for visualization of lesions in patients undergoing colonoscopy to improve overall detection of adenomas and carcinomas.